Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
Sponsor: Regeneron Pharmaceuticals
This PHASE1 trial investigates Advanced Cancer and Advanced Malignancies and is currently completed. Regeneron Pharmaceuticals leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Sep 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Oct 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .